Analysts Set Summit Therapeutics Inc. (NASDAQ:SMMT) Target Price at $34.11
Shares of Summit Therapeutics Inc. (NASDAQ:SMMT – Get Free Report) have been assigned an average rating of “Moderate Buy” from the ten analysts that are presently covering the stock, MarketBeat reports. One analyst has rated the stock with a hold recommendation and nine have assigned a buy recommendation to the company. The average twelve-month price […]
Shares of Summit Therapeutics Inc. (NASDAQ:SMMT – Get Free Report) have been assigned an average rating of “Moderate Buy” from the ten analysts that are presently covering the stock, MarketBeat reports. One analyst has rated the stock with a hold recommendation and nine have assigned a buy recommendation to the company. The average twelve-month price […]
